BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT$8.56 +0.25 (3.01%)
Company News
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
BridgeBio Oncology Therapeutics announced two poster presentations for BBO-10203, a novel small molecule targeting RAS and PI3Kα interactions in cancer treatment, at the San Antonio Breast Cancer Symposium in December 2025.
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia
BridgeBio Oncology Therapeutics presented preclinical data on BBO-10203, a novel RAS:PI3Kα breaker that inhibits KRAS-mutant tumor growth without causing hyperglycemia, showing promising results in monotherapy and combination treatments with KRAS inhibitors.
BBOT to Participate in Upcoming September Investor Healthcare Conferences
BridgeBio Oncology Therapeutics (BBOT) announced participation in two investor conferences in September, focusing on presenting their clinical-stage biopharmaceutical work targeting RAS-pathway malignancies.
